Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$4.14 - $75.50
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$31.03M
Enterprise Value$31.99M
Total Cash (Recent Filing)$552.37K
Total Debt (Recent Filing)$3.10M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Jun 03, 2026EPS Estimate
-2.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.49
Shares Outstanding4,187,505
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-62.82
Enterprise Value/Ebitda-1.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionA material reduction in debt across 2024–2025 lowers interest and refinancing pressure, improving solvency headroom and extending operational runway. That durable improvement enhances financing optionality and reduces near-term liquidity strain versus prior years.
Listing Stability ActionRegaining Nasdaq bid-price compliance via a reverse split preserves the Global Market listing, sustaining access to public capital and institutional visibility. This structural action reduces delisting overhang and supports future financing and investor relations options.
Platform FocusA dedicated CTL T‑cell therapy platform targets high-barrier, high-value indications (cancers, infectious disease). Platform specialization can create durable competitive advantage through technical know-how, regulatory experience, and potential for multiple indications leveraging the same underlying technology.
Bears Say
No RevenueZero revenue across multiple years signals a pre-commercial company still reliant on external capital to fund trials and operations. Without product sales, sustained R&D spending drives dilution risk and dependency on financing, constraining long-term cash self-sufficiency and strategic freedom.
Negative EquityAn equity deficit from accumulated losses weakens the balance sheet, reducing borrowing capacity and increasing sensitivity to adverse shocks. Negative equity can complicate financing terms, heighten covenant risk, and is a persistent solvency concern until profitability or recapitalization occurs.
Listing/Market-Value RiskAn active Nasdaq market-value noncompliance notice (deadlines in Oct 2026) creates sustained listing uncertainty. Potential transfer, additional corporate actions, or delisting risk would impair liquidity, investor access and could materially constrain the company’s ability to raise capital over the next several quarters.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $4.13 and its highest was $75.50 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $31.03M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Jun 03, 2026 which is in 27 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Nov 14, 2025. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.04 by $1.54.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate is -2.64.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,187,505 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.04. Following the earnings report the stock price went down -6.122%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Sold Shares
Worth $6.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
315.97%
Trailing 12-Months
Asset Growth
26.61%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
TVGN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―